1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.
2. • Swain S, Miles D, Kim S-B, Im Y-H, Im S-A, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2020:21(4):519-530. Phase 3 clinical trial which established taxane, trastuzumab, and pertuzumab as the preferred first-line treatment of HER2-positive MBC, final analysis presented here.
3. Miles D, Ciruelos E, Schneeweiss, Puglisi F, Peretz-Yablonski T, Campone M, et al. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol 2021:32(10):1245-1255.
4. Rimawi M, Ferraro J-M, De La Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomised, open-label phase II trial. J Clin Oncol. 2018;36(28):2826–35.
5. Prior L, Lim M, Ward C, Featherstone H, Murray H, D’Arcy C, et al. Metastatic HER2+ breast cancer: a potentially curable disease? Cureus 2017:9(9)e1654.